Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
55°
Mostly Cloudy
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
Photos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Best of 2023
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Regeneron Pharmaceuticals
(NQ:
REGN
)
957.00
+19.39 (+2.07%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 3, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Regeneron Pharmaceuticals
< Previous
1
2
3
4
5
6
7
8
9
...
35
36
Next >
Cantor Fitzgerald Maintains Neutral Rating for Regeneron Pharmaceuticals: Here's What You Need To Know
October 16, 2023
Via
Benzinga
2 Healthcare Stocks Near 52-Week Highs Still Worth Buying
October 16, 2023
These two large-cap biopharma companies could have more room to run.
Via
The Motley Fool
Regeneron to Showcase Progress from Innovative Oncology Portfolio in Several Difficult-to-Treat Cancers at ESMO
October 15, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
AI Stocks AVGO And ANET Lead 5 Resilient Names Near Buy Points
October 14, 2023
Broadcom and Arista lead five stocks sporting a flat base.
Via
Investor's Business Daily
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
The Latest Analyst Ratings for Regeneron Pharmaceuticals
October 11, 2023
Via
Benzinga
Down 45%, Is Intellia a Buy?
October 10, 2023
Intellia's operating in the high-growth field of gene editing.
Via
The Motley Fool
P/E Ratio Insights for Regeneron Pharmaceuticals
October 06, 2023
Via
Benzinga
$100 Invested In This Stock 5 Years Ago Would Be Worth $200 Today
October 04, 2023
Via
Benzinga
Large Cap Biopharmaceuticals-Core Holdings For Your Healthcare Portfolio Until M&A Action Picks Up
October 09, 2023
Healthcare has not been a strong sector in 2023. Despite its history of being defensive in turbulent times the sector has underperformed as higher rates curb buyers sentiment.
Via
Talk Markets
Biotech Sector: On The Verge Of Triumph Or Turmoil?
October 06, 2023
In this article, we delve into the Biotech Sector, exploring its promises, potential pitfalls, and the questions that arise.
Via
Talk Markets
EYLEA® HD (aflibercept) Injection 8 mg Two-year Results from Pivotal PULSAR Trial in Wet Age-related Macular Degeneration Presented at EURETINA
October 05, 2023
First presentation of long-term results demonstrated sustained visual and anatomic improvements among EYLEA HD patients through two years
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
This Market-Beating Stock Just Gave Investors More Reasons to Invest
October 05, 2023
There is a lot going the way of this biotech giant right now.
Via
The Motley Fool
Regeneron Pharmaceuticals Unusual Options Activity
October 03, 2023
Via
Benzinga
Examining the Quality Attributes of NASDAQ:REGN.
September 22, 2023
Why the quality investor may take a look at REGENERON PHARMACEUTICALS (NASDAQ:REGN).
Via
Chartmill
Analyst Expectations for Regeneron Pharmaceuticals's Future
September 21, 2023
Via
Benzinga
Here's the Best Big Pharma Stock of the Decade so Far (and It's Not Even Close)
October 05, 2023
This stock puts the "big" in big pharma after massive gains in recent years.
Via
The Motley Fool
MAIA Secures FDA Clearance Of IND Application For THIO For Non-Small Cell Lung Cancer
October 03, 2023
MAIA Biotechnology, Inc. (AMEX: MAIA) announced that the U.S.
Via
Benzinga
Exposures
Product Safety
Regeneron and Intellia Announce Expanded Research Collaboration to Develop CRISPR-Based Therapies for the Treatment of Neurological and Muscular Diseases
October 03, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
10 Health Care Stocks Whale Activity In Today's Session
October 02, 2023
Via
Benzinga
Stock Split Watch: Is Regeneron Pharmaceuticals Next?
September 30, 2023
If the biotech does split its stock, it will be a first for the company.
Via
The Motley Fool
Odronextamab BLA for Treatment of Relapsed/Refractory Follicular Lymphoma (FL) and Diffuse Large B-cell Lymphoma (DLBCL) Accepted for FDA Priority Review
September 29, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Regeneron to Report Third Quarter 2023 Financial and Operating Results and Host Conference Call and Webcast on November 2, 2023
September 28, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
10 Health Care Stocks With Whale Alerts In Today's Session
September 28, 2023
Via
Benzinga
Three Of Our Top Picks For Your Healthcare Portfolio
September 26, 2023
Amidst macro uncertainty, healthcare stocks should outperform.
Via
Talk Markets
Dupixent® (dupilumab) sBLA for Treatment of Eosinophilic Esophagitis (EoE) in Children Aged 1 to 11 Accepted for FDA Priority Review
September 26, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Regeneron Completes Acquisition of Decibel Therapeutics, Adding Promising Gene Therapy Programs for Hearing Loss
September 25, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Are Gene Therapy Stocks The Market's Next Big Winners?
September 25, 2023
Biotechs Sarepta and BioMarin are among companies advancing cutting-edge gene therapies, although those treatments can come with a $2 million or more price.
Via
MarketBeat
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Argenx's 28% Surge & Promising Product Propel Investor Confidence
September 25, 2023
Argenx's chart is forming a bullish base after a 28% jump after positive clinical trials. Analysts believe the immunology specialist is an acquisition target.
Via
MarketBeat
This Recent FDA Approval Could Give Regeneron's Top Line a Big Boost
September 20, 2023
A higher-dose version of Eylea will help the company fight off competition and increase revenue.
Via
The Motley Fool
Exposures
Product Safety
3 Stocks to Buy to Ride Europe’s Coming Market Surge
September 19, 2023
With Europe’s markets looking to perform better in the second half of 2023, here are three European stocks to buy to ride the wave.
Via
InvestorPlace
< Previous
1
2
3
4
5
6
7
8
9
...
35
36
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.